Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT01194414
Registration number
NCT01194414
Ethics application status
Date submitted
1/09/2010
Date registered
3/09/2010
Date last updated
20/06/2016
Titles & IDs
Public title
A Study to Compare Subcutaneous Versus Intravenous Administration of RoActemra/Actemra (Tocilizumab) in Participants With Moderate to Severe Active Rheumatoid Arthritis
Query!
Scientific title
A Randomized, Double-blind, Parallel Group Study of the Safety and Effect on Clinical Outcome of Tocilizumab SC Versus Tocilizumab IV, in Combination With Traditional Disease Modifying Anti-rheumatic Drugs (DMARDs), in Patients With Moderate to Severe Active Rheumatoid Arthritis
Query!
Secondary ID [1]
0
0
2010-018375-22
Query!
Secondary ID [2]
0
0
WA22762
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Rheumatoid Arthritis
0
0
Query!
Condition category
Condition code
Musculoskeletal
0
0
0
0
Query!
Osteoarthritis
Query!
Inflammatory and Immune System
0
0
0
0
Query!
Rheumatoid arthritis
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - tocilizumab SC
Treatment: Drugs - tocilizumab IV
Treatment: Drugs - placebo to tocilizumab SC
Treatment: Drugs - placebo to tocilizumab IV
Treatment: Drugs - Disease-modifying antirheumatic drugs (DMARDs)
Experimental: Tocilizumab SC - Participants received tocilizumab 162 mg subcutaneous (SC) injection weekly plus placebo to tocilizumab intravenous (IV) infusion every 4 weeks for a total of 24 weeks in the double-blind period. Participants continued to receive tocilizumab 162 mg SC injection weekly for a total of 72 weeks in open label extension period.
Non-biologic disease-modifying anti-rheumatic drugs (DMARDs) at a stable dose continued throughout the study.
Experimental: Tocilizumab IV - Participants received tocilizumab 8 mg/kg infusion (IV) every 4 weeks plus placebo to tocilizumab SC injection weekly for a total of 24 weeks in the double-blind period. Participants continued to receive tocilizumab 8 mg/kg IV infusion every 4 weeks for a total of 72 weeks in open label extension period.
Non-biologic disease-modifying anti-rheumatic drugs (DMARDs) at a stable dose continued throughout the study.
Experimental: Tocilizumab SC Then Tocilizumab IV - Participants who received tocilizumab 162 mg subcutaneous (SC) injection weekly plus placebo to tocilizumab IV infusion every 4 weeks for 24 weeks in double blind treatment period switched to tocilizumab 8 mg/kg IV infusion every 4 weeks for a total of 72 weeks in open label extension period.
Non-biologic disease-modifying anti-rheumatic drugs (DMARDs) at a stable dose continued throughout the study.
Experimental: Tocilizumab IV Then Tocilizumab SC - Participants who received tocilizumab 8 mg/kg infusion (IV) every 4 weeks plus placebo to tocilizumab SC injection weekly in double blind treatment period switched to tocilizumab 162 mg SC injection weekly for a total of 72 weeks in open label extension period.
Non-biologic disease-modifying anti-rheumatic drugs (DMARDs) at a stable dose will be continued throughout the study.
Treatment: Drugs: tocilizumab SC
Tocilizumab supplied in a single-use pre-filled syringe, with a needle safety device, delivering 162 mg/0.9 mL solution for subcutaneous injection once a week.
Treatment: Drugs: tocilizumab IV
Tocilizumab supplied in vials as a sterile solution for 8 mg/kg intravenous infusion every 4 weeks.
Treatment: Drugs: placebo to tocilizumab SC
Placebo tocilizumab supplied as a single-use pre-filled syringe with a needle safety device, delivering 0.9 mL sodium chloride for subcutaneous injection once a week for 24 weeks in the double-blind period.
Treatment: Drugs: placebo to tocilizumab IV
Placebo to tocilizumab supplied as a solution in 10 mL vials containing polysorbate 80 and sucrose in water for infusion every 4 weeks for a total of 24 weeks in the double-blind period.
Treatment: Drugs: Disease-modifying antirheumatic drugs (DMARDs)
stable dose as prescribed
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Percentage of Participants Achieving an American College of Rheumatology Criteria (ACR20) Response at Week 24
Query!
Assessment method [1]
0
0
ACR20 response is defined as a = 20% improvement (reduction) compared with baseline for both total joint count-68 joints (TJC68) and swollen joint count-66 joints (SJC66), as well as for three of the five additional ACR core set variables: Patient's Assessment of Pain over the previous 24 hours using a Visual Analog Scale (VAS) where left end of the line 0=no pain to right end of the line 100=unbearable pain; Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a VAS where left end of the line 0=no disease activity to right end of the line 100=maximum disease activity; Health Assessment Questionnaire: 20 questions in 8 areas (dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities) answered on a scale of 0=without difficulty to 3=unable to do; and acute-phase reactant (either C-reactive protein \[CRP\] or Erythrocyte Sedimentation Rate \[ESR\]).
Query!
Timepoint [1]
0
0
Baseline, 24 weeks
Query!
Primary outcome [2]
0
0
Percentage of Participants With Adverse Events, Serious Adverse Events and Clinically Significant Laboratory Assessments
Query!
Assessment method [2]
0
0
Query!
Timepoint [2]
0
0
Baseline to up to 3 months after last dose of study drug (approximately up to 2 years)
Query!
Secondary outcome [1]
0
0
Percentage of Participants Achieving an American College of Rheumatology Criteria (ACR50) Response at Week 24
Query!
Assessment method [1]
0
0
ACR50 response is defined as a = 50% improvement (reduction) compared with baseline for both total joint count-68 joints (TJC68) and swollen joint count-66 joints (SJC66), as well as for three of the five additional ACR core set variables: Patient's Assessment of Pain over the previous 24 hours using a Visual Analog Scale (VAS) where left end of the line 0=no pain to right end of the line 100=unbearable pain; Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a VAS where left end of the line 0=no disease activity to right end of the line 100=maximum disease activity; Health Assessment Questionnaire: 20 questions in 8 areas (dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities) answered on a scale of 0=without difficulty to 3=unable to do; and acute-phase reactant (either C-reactive protein or Erythrocyte Sedimentation Rate).
Query!
Timepoint [1]
0
0
Baseline, 24 weeks
Query!
Secondary outcome [2]
0
0
Percentage of Participants Achieving an American College of Rheumatology Criteria (ACR70) Response at Week 24
Query!
Assessment method [2]
0
0
ACR70 response is defined as a = 70% improvement (reduction) compared with baseline for both total joint count-68 joints (TJC68) and swollen joint count-66 joints (SJC66), as well as for three of the five additional ACR core set variables: Patient's Assessment of Pain over the previous 24 hours using a Visual Analog Scale (VAS) where left end of the line 0=no pain to right end of the line 100=unbearable pain; Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a VAS where left end of the line 0=no disease activity to right end of the line 100=maximum disease activity; Health Assessment Questionnaire: 20 questions in 8 areas (dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities) answered on a scale of 0=without difficulty to 3=unable to do; and acute-phase reactant (either C-reactive protein or Erythrocyte Sedimentation Rate).
Query!
Timepoint [2]
0
0
Baseline, 24 weeks
Query!
Secondary outcome [3]
0
0
Percentage of Participants With Disease Activity Score 28 (DAS28) Remission at Week 24
Query!
Assessment method [3]
0
0
The DAS28 (ESR) score is a measure of the subject's disease activity. It is calculated using the tender joint count (28 joints), swollen joint count (28 joints), patient's global assessment of disease activity VAS where left side of the line 0=no disease activity to right side of the line 100=extreme disease activity and ESR. DAS28-(ESR) total scores range from 0 - 10. Remission is defined as achieving a DAS28-ESR score of less than 2.6.
Query!
Timepoint [3]
0
0
Week 24
Query!
Secondary outcome [4]
0
0
Percentage of Participants Achieving a Decrease of = 0.3 in the Health Assessment Questionnaire-Disability Index (HAQ-DI) From Baseline to Week 24
Query!
Assessment method [4]
0
0
The Stanford Health Assessment Questionnaire disability index (HAQ-DI) is a participant completed questionnaire specific for rheumatoid arthritis. It consists of 20 questions referring to 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip and common daily activities. Each domain has at least two component questions. There are four possible responses for each component ranging from 0(without any difficulty) to 4 (unable to do).HAQ-DI=sum of worst scores in each domain divided by the number of domains answered. A decrease indicates improvement.
Query!
Timepoint [4]
0
0
Baseline, 24 Weeks
Query!
Secondary outcome [5]
0
0
Percentage of Participants Who Withdrew Because of Lack of Therapeutic Response at Week 24
Query!
Assessment method [5]
0
0
The percentage of participants who withdrew from the study because they were not responding to treatment with the study drug.
Query!
Timepoint [5]
0
0
24 Weeks
Query!
Secondary outcome [6]
0
0
Percentage of Participants With American College of Rheumatology Criteria (ACR20, ACR50, ACR70) at Week 97
Query!
Assessment method [6]
0
0
ACR20, ACR50 and ACR70: =20%, =50% and =70% reduction from baseline for both TJC68 and SJC66, as well as for 3 of 5 additional ACR variables: Patient's Assessment of Pain in last 24 hours using a Visual Analog Scale (VAS) (0=no pain and 100=unbearable pain); Patient's and Physician's Global Assessment of Disease Activity in last 24 hours using a VAS (0=no disease activity and100=maximum disease activity); Health Assessment Questionnaire: 20 questions in 8 areas (dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities) answered on a scale of 0=without difficulty to 3=unable to do; and acute-phase reactant (either CRP or ESR). CRP was used for calculation of ACR. If missing, ESR was used. LOCF was used for missing joint counts, no imputation for other ACR components.
Query!
Timepoint [6]
0
0
Week 97
Query!
Secondary outcome [7]
0
0
Percentage of Participants With Disease Activity Score 28 (DAS28) Remission at Week 97
Query!
Assessment method [7]
0
0
The DAS28 (ESR) score is a measure of the subject's disease activity. It is calculated using the tender joint count (28 joints), swollen joint count (28 joints), patient's global assessment of disease activity VAS where left side of the line 0=no disease activity to right side of the line 100=extreme disease activity and ESR. DAS28-(ESR) total scores range from 0 - 10. Remission is defined as achieving a DAS28-ESR score of less than 2.6. LOCF used for tender and swollen joint counts, no imputation used for ESR and Patient's Global Assessment of Disease Activity VAS.
Query!
Timepoint [7]
0
0
Week 97
Query!
Secondary outcome [8]
0
0
Percentage of Participants Achieving a Decrease of =0.3 in the Health Assessment Questionnaire-Disability Index (HAQ-DI) From Baseline to Week 97
Query!
Assessment method [8]
0
0
The Stanford Health Assessment Questionnaire disability index (HAQ-DI) is a patient completed questionnaire specific for rheumatoid arthritis. It consists of 20 questions referring to 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip and common daily activities. Each domain has at least two component questions. There are four possible responses for each component ranging from 0(without any difficulty) to 4 (unable to do).HAQ-DI=sum of worst scores in each domain divided by the number of domains answered. A decrease indicates improvement. No imputation of missing scores was made other than for missing baseline scores, for which last score prior to baseline will be carried forward. For participants who prematurely withdrew, data collected at withdrawal visit was used and data thereafter is missing.
Query!
Timepoint [8]
0
0
Baseline, Week 97
Query!
Secondary outcome [9]
0
0
Percentage of Participants Who Withdrew Because of Lack of Therapeutic Response at Week 97
Query!
Assessment method [9]
0
0
The percentage of participants who withdrew from the study because they were not responding to treatment with the study drug.
Query!
Timepoint [9]
0
0
Week 97
Query!
Secondary outcome [10]
0
0
Area Under the Serum Concentration Curve of Tocilizumab After First SC Injection or IV Infusion
Query!
Assessment method [10]
0
0
Query!
Timepoint [10]
0
0
Week 0: at 6 hours (hr), 24 hr, 48 hr, 96 hr, 120 hr and 168 hr after first dose
Query!
Secondary outcome [11]
0
0
Area Under the Serum Concentration Curve of Tocilizumab at Steady State for SC and IV Treatment
Query!
Assessment method [11]
0
0
Query!
Timepoint [11]
0
0
Week 20: at 6 hours (hr), 24 hr, 48 hr, 96 hr, 120 hr and 168 hr after dose.
Query!
Secondary outcome [12]
0
0
Minimum Serum Concentration (Cmin) of Tocilizumab
Query!
Assessment method [12]
0
0
Query!
Timepoint [12]
0
0
Week 0, Week 20: at 6 hours (hr), 24 hr, 48 hr, 96 hr, 120 hr and 168 hr after dose
Query!
Secondary outcome [13]
0
0
Maximum Serum Concentration (Cmax) of Tocilizumab
Query!
Assessment method [13]
0
0
Query!
Timepoint [13]
0
0
Week 0, Week 20: at 6 hours (hr), 24 hr, 48 hr, 96 hr, 120 hr and 168 hr after dose
Query!
Secondary outcome [14]
0
0
Time to Maximum Serum Concentration (Tmax) of Tocilizumab
Query!
Assessment method [14]
0
0
Query!
Timepoint [14]
0
0
Week 0, Week 20: at 6 hours (hr), 24 hr, 48 hr, 96 hr, 120 hr and 168 hr after dose
Query!
Secondary outcome [15]
0
0
Change From Baseline in Serum Interleukin-6 (IL-6) Concentration at Week 25
Query!
Assessment method [15]
0
0
Query!
Timepoint [15]
0
0
Baseline, Week 25
Query!
Secondary outcome [16]
0
0
Change From Baseline in Serum Soluble Interleukin-6 Receptor (sIL-6R) Concentration at Week 97
Query!
Assessment method [16]
0
0
Query!
Timepoint [16]
0
0
Baseline, Week 97
Query!
Secondary outcome [17]
0
0
Percentage of Participants Who Developed Antibodies To Tocilizumab at Week 97
Query!
Assessment method [17]
0
0
Query!
Timepoint [17]
0
0
Week 97
Query!
Eligibility
Key inclusion criteria
* Adult participants, = 18 years of age
* Rheumatoid arthritis of = 6 months duration, according to American College of Rheumatology (ACR) criteria
* Swollen joint count (SJC) = 4 (66 joint count), tender joint count (TJC) = 4 (68 joint count) at screening and baseline
* Inadequate response to current DMARD therapy
* Permitted DMARDs must be at stable dose for = 8 weeks prior to baseline
* Oral corticosteroids (= 10 mg/day prednisone or equivalent) and NSAIDs (up to maximum recommended dose) must be at stable dose for = 4 weeks prior to baseline
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
* Major surgery (including joint surgery) within 8 weeks prior to screening or planned major surgery within 6 months following randomization
* Rheumatic autoimmune disease other than RA
* Functional class IV (ACR classification)
* Diagnosis of juvenile idiopathic arthritis (JIA) or juvenile rheumatoid arthritis (JRA) and/or RA before the age of 16
* Prior history of or current inflammatory joint disease other than RA
* Intra-articular or parenteral corticosteroids within 4 weeks prior to baseline
* Previous treatment with tocilizumab
* Active current or history of recurrent infection
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/09/2010
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/08/2013
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
1262
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment hospital [1]
0
0
- Adelaide
Query!
Recruitment hospital [2]
0
0
- Clayton
Query!
Recruitment hospital [3]
0
0
- Geelong
Query!
Recruitment hospital [4]
0
0
- Hobart
Query!
Recruitment hospital [5]
0
0
- Malvern East
Query!
Recruitment hospital [6]
0
0
- Maroochydore
Query!
Recruitment hospital [7]
0
0
- New Lambton
Query!
Recruitment postcode(s) [1]
0
0
5011 - Adelaide
Query!
Recruitment postcode(s) [2]
0
0
5041 - Adelaide
Query!
Recruitment postcode(s) [3]
0
0
3168 - Clayton
Query!
Recruitment postcode(s) [4]
0
0
3220 - Geelong
Query!
Recruitment postcode(s) [5]
0
0
7000 - Hobart
Query!
Recruitment postcode(s) [6]
0
0
3145 - Malvern East
Query!
Recruitment postcode(s) [7]
0
0
4558 - Maroochydore
Query!
Recruitment postcode(s) [8]
0
0
2305 - New Lambton
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Arizona
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
California
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Colorado
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Connecticut
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Florida
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Idaho
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Illinois
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Kansas
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Louisiana
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Michigan
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Minnesota
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Missouri
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
New Hampshire
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
New Jersey
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
New Mexico
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
New York
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
North Carolina
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
Ohio
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
Oklahoma
Query!
Country [21]
0
0
United States of America
Query!
State/province [21]
0
0
Pennsylvania
Query!
Country [22]
0
0
United States of America
Query!
State/province [22]
0
0
South Carolina
Query!
Country [23]
0
0
United States of America
Query!
State/province [23]
0
0
Tennessee
Query!
Country [24]
0
0
United States of America
Query!
State/province [24]
0
0
Texas
Query!
Country [25]
0
0
United States of America
Query!
State/province [25]
0
0
Washington
Query!
Country [26]
0
0
Argentina
Query!
State/province [26]
0
0
Buenos Aires
Query!
Country [27]
0
0
Argentina
Query!
State/province [27]
0
0
Rosario
Query!
Country [28]
0
0
Brazil
Query!
State/province [28]
0
0
Curitiba
Query!
Country [29]
0
0
Brazil
Query!
State/province [29]
0
0
Goiania
Query!
Country [30]
0
0
Brazil
Query!
State/province [30]
0
0
Juiz de Fora
Query!
Country [31]
0
0
Brazil
Query!
State/province [31]
0
0
Porto Alegre
Query!
Country [32]
0
0
Brazil
Query!
State/province [32]
0
0
Sao Paulo
Query!
Country [33]
0
0
Brazil
Query!
State/province [33]
0
0
São Paulo
Query!
Country [34]
0
0
Bulgaria
Query!
State/province [34]
0
0
Sofia
Query!
Country [35]
0
0
Canada
Query!
State/province [35]
0
0
Alberta
Query!
Country [36]
0
0
Canada
Query!
State/province [36]
0
0
British Columbia
Query!
Country [37]
0
0
Canada
Query!
State/province [37]
0
0
Newfoundland and Labrador
Query!
Country [38]
0
0
Canada
Query!
State/province [38]
0
0
Ontario
Query!
Country [39]
0
0
Canada
Query!
State/province [39]
0
0
Quebec
Query!
Country [40]
0
0
Canada
Query!
State/province [40]
0
0
Saskatchewan
Query!
Country [41]
0
0
Colombia
Query!
State/province [41]
0
0
Barranquilla
Query!
Country [42]
0
0
Colombia
Query!
State/province [42]
0
0
Bogota
Query!
Country [43]
0
0
Colombia
Query!
State/province [43]
0
0
Bogotá
Query!
Country [44]
0
0
France
Query!
State/province [44]
0
0
Bordeaux
Query!
Country [45]
0
0
France
Query!
State/province [45]
0
0
Le Mans
Query!
Country [46]
0
0
France
Query!
State/province [46]
0
0
Marseille
Query!
Country [47]
0
0
France
Query!
State/province [47]
0
0
Montpellier
Query!
Country [48]
0
0
France
Query!
State/province [48]
0
0
Nantes
Query!
Country [49]
0
0
France
Query!
State/province [49]
0
0
Paris
Query!
Country [50]
0
0
France
Query!
State/province [50]
0
0
Strasbourg
Query!
Country [51]
0
0
France
Query!
State/province [51]
0
0
Toulouse
Query!
Country [52]
0
0
Germany
Query!
State/province [52]
0
0
Bad Bramstedt
Query!
Country [53]
0
0
Germany
Query!
State/province [53]
0
0
Berlin
Query!
Country [54]
0
0
Germany
Query!
State/province [54]
0
0
Dresden
Query!
Country [55]
0
0
Germany
Query!
State/province [55]
0
0
Essen
Query!
Country [56]
0
0
Germany
Query!
State/province [56]
0
0
Freiburg
Query!
Country [57]
0
0
Germany
Query!
State/province [57]
0
0
Gommern
Query!
Country [58]
0
0
Germany
Query!
State/province [58]
0
0
Heidelberg
Query!
Country [59]
0
0
Germany
Query!
State/province [59]
0
0
Herne
Query!
Country [60]
0
0
Germany
Query!
State/province [60]
0
0
Hildesheim
Query!
Country [61]
0
0
Germany
Query!
State/province [61]
0
0
Köln
Query!
Country [62]
0
0
Germany
Query!
State/province [62]
0
0
Ludwigshafen
Query!
Country [63]
0
0
Germany
Query!
State/province [63]
0
0
Osnabrück
Query!
Country [64]
0
0
Germany
Query!
State/province [64]
0
0
Ratingen
Query!
Country [65]
0
0
Germany
Query!
State/province [65]
0
0
Rostock
Query!
Country [66]
0
0
Germany
Query!
State/province [66]
0
0
Würzburg
Query!
Country [67]
0
0
Guatemala
Query!
State/province [67]
0
0
Guatemala City
Query!
Country [68]
0
0
Hong Kong
Query!
State/province [68]
0
0
Hong Kong
Query!
Country [69]
0
0
Italy
Query!
State/province [69]
0
0
Arenzano
Query!
Country [70]
0
0
Italy
Query!
State/province [70]
0
0
Bergamo
Query!
Country [71]
0
0
Italy
Query!
State/province [71]
0
0
Catania
Query!
Country [72]
0
0
Italy
Query!
State/province [72]
0
0
Cona (ferrara)
Query!
Country [73]
0
0
Italy
Query!
State/province [73]
0
0
Genova
Query!
Country [74]
0
0
Italy
Query!
State/province [74]
0
0
Napoli
Query!
Country [75]
0
0
Italy
Query!
State/province [75]
0
0
Pavia
Query!
Country [76]
0
0
Italy
Query!
State/province [76]
0
0
Pisa
Query!
Country [77]
0
0
Italy
Query!
State/province [77]
0
0
Potenza
Query!
Country [78]
0
0
Italy
Query!
State/province [78]
0
0
Reggio Emilia
Query!
Country [79]
0
0
Italy
Query!
State/province [79]
0
0
Udine
Query!
Country [80]
0
0
Italy
Query!
State/province [80]
0
0
Varese
Query!
Country [81]
0
0
Lithuania
Query!
State/province [81]
0
0
Klaipeda
Query!
Country [82]
0
0
Lithuania
Query!
State/province [82]
0
0
Siauliai
Query!
Country [83]
0
0
Lithuania
Query!
State/province [83]
0
0
Vilnius
Query!
Country [84]
0
0
Mexico
Query!
State/province [84]
0
0
Culiacan
Query!
Country [85]
0
0
Mexico
Query!
State/province [85]
0
0
Guadalajara
Query!
Country [86]
0
0
Mexico
Query!
State/province [86]
0
0
Leon
Query!
Country [87]
0
0
Mexico
Query!
State/province [87]
0
0
Merida
Query!
Country [88]
0
0
Mexico
Query!
State/province [88]
0
0
Mexico Ctiy
Query!
Country [89]
0
0
Mexico
Query!
State/province [89]
0
0
Miexico City
Query!
Country [90]
0
0
Mexico
Query!
State/province [90]
0
0
Morelia
Query!
Country [91]
0
0
Mexico
Query!
State/province [91]
0
0
Obregon
Query!
Country [92]
0
0
Mexico
Query!
State/province [92]
0
0
Queretaro
Query!
Country [93]
0
0
Mexico
Query!
State/province [93]
0
0
Saltillo
Query!
Country [94]
0
0
Mexico
Query!
State/province [94]
0
0
Torreon
Query!
Country [95]
0
0
New Zealand
Query!
State/province [95]
0
0
Auckland
Query!
Country [96]
0
0
New Zealand
Query!
State/province [96]
0
0
Hamilton
Query!
Country [97]
0
0
New Zealand
Query!
State/province [97]
0
0
Tauranga
Query!
Country [98]
0
0
New Zealand
Query!
State/province [98]
0
0
Wellington
Query!
Country [99]
0
0
Peru
Query!
State/province [99]
0
0
Lima 01
Query!
Country [100]
0
0
Peru
Query!
State/province [100]
0
0
Lima
Query!
Country [101]
0
0
Philippines
Query!
State/province [101]
0
0
Cebu
Query!
Country [102]
0
0
Philippines
Query!
State/province [102]
0
0
Manila
Query!
Country [103]
0
0
Philippines
Query!
State/province [103]
0
0
Quezon
Query!
Country [104]
0
0
Poland
Query!
State/province [104]
0
0
Bialystok
Query!
Country [105]
0
0
Poland
Query!
State/province [105]
0
0
Lublin
Query!
Country [106]
0
0
Poland
Query!
State/province [106]
0
0
Poznan
Query!
Country [107]
0
0
Poland
Query!
State/province [107]
0
0
Warszawa
Query!
Country [108]
0
0
Puerto Rico
Query!
State/province [108]
0
0
Ponce
Query!
Country [109]
0
0
Romania
Query!
State/province [109]
0
0
Bucharest
Query!
Country [110]
0
0
Romania
Query!
State/province [110]
0
0
Bucuresti
Query!
Country [111]
0
0
Romania
Query!
State/province [111]
0
0
Iasi
Query!
Country [112]
0
0
Russian Federation
Query!
State/province [112]
0
0
Moscow
Query!
Country [113]
0
0
Russian Federation
Query!
State/province [113]
0
0
Novosibirsk
Query!
Country [114]
0
0
Russian Federation
Query!
State/province [114]
0
0
Ryazan
Query!
Country [115]
0
0
Russian Federation
Query!
State/province [115]
0
0
St Petersburg
Query!
Country [116]
0
0
Russian Federation
Query!
State/province [116]
0
0
Ulyanovsk
Query!
Country [117]
0
0
Russian Federation
Query!
State/province [117]
0
0
Yaroslavl
Query!
Country [118]
0
0
Singapore
Query!
State/province [118]
0
0
Singapore
Query!
Country [119]
0
0
South Africa
Query!
State/province [119]
0
0
Cape Town
Query!
Country [120]
0
0
South Africa
Query!
State/province [120]
0
0
Durban
Query!
Country [121]
0
0
South Africa
Query!
State/province [121]
0
0
Parktown
Query!
Country [122]
0
0
South Africa
Query!
State/province [122]
0
0
Port Elizabeth
Query!
Country [123]
0
0
South Africa
Query!
State/province [123]
0
0
Stellenbosch
Query!
Country [124]
0
0
Spain
Query!
State/province [124]
0
0
Barakaldo
Query!
Country [125]
0
0
Spain
Query!
State/province [125]
0
0
Bilbao
Query!
Country [126]
0
0
Spain
Query!
State/province [126]
0
0
La Coruna
Query!
Country [127]
0
0
Spain
Query!
State/province [127]
0
0
La Laguna
Query!
Country [128]
0
0
Spain
Query!
State/province [128]
0
0
Madrid
Query!
Country [129]
0
0
Spain
Query!
State/province [129]
0
0
Malaga
Query!
Country [130]
0
0
Spain
Query!
State/province [130]
0
0
Merida
Query!
Country [131]
0
0
Spain
Query!
State/province [131]
0
0
Santander
Query!
Country [132]
0
0
Spain
Query!
State/province [132]
0
0
Santiago de Compostela
Query!
Country [133]
0
0
Spain
Query!
State/province [133]
0
0
Sevilla
Query!
Country [134]
0
0
Spain
Query!
State/province [134]
0
0
Torrelavega
Query!
Country [135]
0
0
Spain
Query!
State/province [135]
0
0
Valencia
Query!
Country [136]
0
0
Thailand
Query!
State/province [136]
0
0
Bangkok
Query!
Country [137]
0
0
Thailand
Query!
State/province [137]
0
0
Chiang Mai
Query!
Country [138]
0
0
Thailand
Query!
State/province [138]
0
0
Khon Kaen
Query!
Country [139]
0
0
United Kingdom
Query!
State/province [139]
0
0
Cambridge
Query!
Country [140]
0
0
United Kingdom
Query!
State/province [140]
0
0
Cannock
Query!
Country [141]
0
0
United Kingdom
Query!
State/province [141]
0
0
Coventry
Query!
Country [142]
0
0
United Kingdom
Query!
State/province [142]
0
0
Eastbourne
Query!
Country [143]
0
0
United Kingdom
Query!
State/province [143]
0
0
Exeter
Query!
Country [144]
0
0
United Kingdom
Query!
State/province [144]
0
0
Harrogate
Query!
Country [145]
0
0
United Kingdom
Query!
State/province [145]
0
0
Ipswich
Query!
Country [146]
0
0
United Kingdom
Query!
State/province [146]
0
0
London
Query!
Country [147]
0
0
United Kingdom
Query!
State/province [147]
0
0
Middlesborough
Query!
Country [148]
0
0
United Kingdom
Query!
State/province [148]
0
0
Newcastle Upon Tyne
Query!
Country [149]
0
0
United Kingdom
Query!
State/province [149]
0
0
Northampton
Query!
Country [150]
0
0
United Kingdom
Query!
State/province [150]
0
0
Nottingham
Query!
Country [151]
0
0
United Kingdom
Query!
State/province [151]
0
0
Westcliffe-on-sea
Query!
Country [152]
0
0
United Kingdom
Query!
State/province [152]
0
0
Wirral
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Hoffmann-La Roche
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This randomized, double-blind, parallel group study compares the efficacy and safety of subcutaneous (sc) versus intravenous (iv) administration of tocilizumab in participants with moderate to severe active rheumatoid arthritis. Participants were randomized to receive either tocilizumab 162 mg sc weekly plus iv placebo every 4 weeks, or tocilizumab 8 mg/kg iv every 4 weeks plus sc placebo weekly during the double-blind period from baseline to Week 24. The double-blind period was followed by a 72-week open-label treatment with some switching of sc and iv administration. No placebo was administered in the open-label phase. Participants continued on their stable dose of disease-modifying antirheumatic drugs (DMARDs) throughout the study. Anticipated time on study treatment was 2 years.
Query!
Trial website
https://clinicaltrials.gov/study/NCT01194414
Query!
Trial related presentations / publications
Burmester GR, Rubbert-Roth A, Cantagrel A, Hall S, Leszczynski P, Feldman D, Rangaraj MJ, Roane G, Ludivico C, Bao M, Rowell L, Davies C, Mysler EF. Efficacy and safety of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional DMARDs in patients with RA at week 97 (SUMMACTA). Ann Rheum Dis. 2016 Jan;75(1):68-74. doi: 10.1136/annrheumdis-2015-207281. Epub 2015 Jun 8.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Clinical Trials
Query!
Address
0
0
Hoffmann-La Roche
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results are available at
https://clinicaltrials.gov/study/NCT01194414
Download to PDF